These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38350430)
1. Evaluation of a Multimodal Stress Management and Comprehensive Lifestyle Modification Program on Quality of Life and Gastrointestinal Symptoms in Patients with Crohn's Disease: A Randomized Controlled Pilot Trial with 9-Month Follow-Up. Bauer N; Löffler C; Oeznur O; Uecker C; Schlee C; Adamczyk A; Elsenbruch S; Pfuhlmann K; Reissmann R; Westendorf A; Keil T; Langhorst J Digestion; 2024; 105(3):201-212. PubMed ID: 38350430 [TBL] [Abstract][Full Text] [Related]
2. Mind-body-medicine and comprehensive lifestyle-modification in patients with Crohn's disease-Feasibility of a randomized controlled trial under pandemic circumstances. Bauer N; Löffler C; Öznur Ö; Uecker C; Keil T; Langhorst J Front Integr Neurosci; 2022; 16():960301. PubMed ID: 36081609 [TBL] [Abstract][Full Text] [Related]
3. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomized controlled trial. Boye B; Lundin KE; Jantschek G; Leganger S; Mokleby K; Tangen T; Jantschek I; Pripp AH; Wojniusz S; Dahlstroem A; Rivenes AC; Benninghoven D; Hausken T; Roseth A; Kunzendorf S; Wilhelmsen I; Sharpe M; Blomhoff S; Malt UF; Jahnsen J Inflamm Bowel Dis; 2011 Sep; 17(9):1863-73. PubMed ID: 21287660 [TBL] [Abstract][Full Text] [Related]
4. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up. Langhorst J; Mueller T; Luedtke R; Franken U; Paul A; Michalsen A; Schedlowski M; Dobos GJ; Elsenbruch S Scand J Gastroenterol; 2007 Jun; 42(6):734-45. PubMed ID: 17505996 [TBL] [Abstract][Full Text] [Related]
5. Optimizing management of Crohn's disease within a project management framework: results of a pilot study. Keefer L; Doerfler B; Artz C Inflamm Bowel Dis; 2012 Feb; 18(2):254-60. PubMed ID: 21351218 [TBL] [Abstract][Full Text] [Related]
6. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease. Zhou S; Huang Z; Hou W; Lin Y; Yu J Inflamm Res; 2024 Feb; 73(2):199-209. PubMed ID: 38168701 [TBL] [Abstract][Full Text] [Related]
7. Effects of lifestyle modification on coronary artery calcium progression and prognostic factors in coronary patients--3-year results of the randomized SAFE-LIFE trial. Lehmann N; Paul A; Moebus S; Budde T; Dobos GJ; Michalsen A Atherosclerosis; 2011 Dec; 219(2):630-6. PubMed ID: 21944697 [TBL] [Abstract][Full Text] [Related]
14. Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's disease. Seeger WA; Thieringer J; Esters P; Allmendinger B; Stein J; Schulze H; Dignass A United European Gastroenterol J; 2020 Aug; 8(7):804-813. PubMed ID: 32580666 [TBL] [Abstract][Full Text] [Related]
15. Cannabis for the treatment of Crohn's disease. Kafil TS; Nguyen TM; MacDonald JK; Chande N Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616 [TBL] [Abstract][Full Text] [Related]
16. The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease? Boye B; Jahnsen J; Mokleby K; Leganger S; Jantschek G; Jantschek I; Kunzendorf S; Benninghoven D; Wilhelmsen I; Sharpe M; Blomhoff S; Malt UF; Lundin KE Inflamm Bowel Dis; 2008 May; 14(5):680-6. PubMed ID: 18509900 [TBL] [Abstract][Full Text] [Related]
17. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339 [TBL] [Abstract][Full Text] [Related]
18. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease. Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288 [TBL] [Abstract][Full Text] [Related]
19. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863 [TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]